OrthoPediatrics Corp.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a KIDS research report →
Range $22 – $38
Price Chart
About the company
OrthoPediatrics Corp. is a medical technology firm dedicated to the design, development, and global commercialization of specialized implants and devices. These products are meticulously crafted to be anatomically appropriate for treating children affected by orthopedic conditions across the United States and internationally.
- CEO
- David R. Bailey
- IPO
- 2017
- Employees
- 602
- HQ
- Warsaw, IN, US
Get TickerSpark's AI analysis on KIDS
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
- Market Cap
- $828.75M
- P/E
- -22.20
- Fwd P/E
- 34.88
- PEG
- -0.72
- P/S
- 3.14
- P/B
- 2.26
- EV/EBITDA
- 374.01
- Div Yield
- 0.00%
- Gross Margin
- 73.76%
- Op Margin
- -8.38%
- Net Margin
- -12.83%
- ROE
- -9.91%
- ROIC
- -4.88%
Latest fiscal year · YoY change
- Revenue
- $236.35M+15.4%
- Gross Profit
- $172.66M+16.2%
- Op Income
- $-28,999,000
- Net Income
- $-39,648,000-4.8%
- EPS
- $-1.69-3.0%
- OCF Growth
- +82.1%
- FCF Growth
- +61.4%
- 52W High
- $34.53
- 52W Low
- $14.42
- 50D MA
- $25.86
- 200D MA
- $20.58
- Beta
- 0.87
- RSI (14)
- 64
- Avg Volume
- 278.04K
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
OrthoPediatrics posted record third-quarter revenue growth and record adjusted EBITDA, while keeping 2026 guidance conservative and pointing to a larger 2027-2028 product-launch runway.· October 27, 2026
- Record Q3 revenue was $72.7 million, up 19% year over year, with growth across implants, OPSB, scoliosis, and international.
- Gross margin held at 74%, adjusted EBITDA hit a record $6.9 million, and free cash flow turned positive at $1.6 million.
- Management raised full-year 2026 revenue guidance to $270 million-$273 million and reiterated adjusted EBITDA of about $25 million.
- The “super cycle” pipeline is still early: 3P Hip is in full launch, while 3P Small, 3P Mini, PNP Retrograde, VerteGlide, and eLLi are expected to add more meaningfully in 2027 and beyond.
- OPSB continues to outperform, with growth above 20%, over 60 clinics, and 34 OPSB systems versus 31 at the start of the year.
Third-quarter 2026 revenue was a record $72.7 million, up 19% from $61.2 million in Q3 2025. US revenue was $57.9 million, up 19% from $48.7 million, and international revenue was $14.8 million, up 18% from $12.5 million. Trauma and deformity revenue was $52.6 million, up 19% from $44.1 million; scoliosis revenue was $19.2 million, up 18% from $16.3 million; sports medicine/other revenue was $0.9 million versus $0.8 million. Gross margin was 74%, flat year over year. GAAP net loss per share was $0.25 versus $0.50 a year ago, and non-GAAP net loss per share was $0.23 versus $0.24. Adjusted EBITDA was a record $6.9 million versus $6.2 million, with margin of about 10%. Free cash flow was positive $1.6 million versus $3.4 million used in Q3 2025. Cash, short-term investments, and restricted cash totaled $45 million, with another $20 million of term loan availability. Full-year 2026 guidance was raised to $270 million-$273 million in revenue, representing 14%-16% growth, while adjusted EBITDA guidance was reiterated at about $25 million. Management expects approximately $10 million of set deployment and free cash flow break-even or better in 2026, with positive free cash flow in 2027 and beyond.
David Bailey framed the quarter as an “outstanding” one and emphasized that the company’s core mission metric is helping children, citing nearly 42 thousand kids helped in the quarter and more than 1.4 million total. He stressed that the business is still early in a multiyear innovation super cycle, with several products only in limited launch and larger growth expected in 2027 and beyond. His tone was upbeat but measured: he repeatedly highlighted conservative capital deployment, free-cash-flow discipline, and confidence in the long runway ahead.
Fred Hite focused on the financial leverage emerging in the model. He cited 19% revenue growth to $72.7 million, 74% gross margin, $6.9 million of adjusted EBITDA, and positive free cash flow of $1.6 million; he also noted $45 million of cash/short-term investments/restricted cash and $20 million of remaining term-loan capacity. He said operating expenses rose mainly because of sales commissions, clinic expansion, and small acquisitions, but reiterated that 2026 EBITDA guidance remains about $25 million and that the company expects roughly $10 million of set deployment and breakeven-or-better free cash flow for the year.
Analysts pressed on whether the fourth quarter and 2027 guidance could prove conservative given share gains, new-product momentum, and OPSB strength. Management said it is intentionally staying cautious because Q4 can be affected by factors like Brazil set sales and 70-unit sales, and it does not want to bake in those items aggressively. On profitability, management said the new products should improve ASPs, margins, contracting leverage, and cash conversion, while clinic expansion will support growth but also carries upfront expense. Questions also covered VerteGlide, eLLi, clinic expansion, and international growth; management said VerteGlide adoption is broadening, eLLi is waiting on FDA/IDE timing and is more of a 2028-2029 story, and international growth is being driven mostly by legacy product demand and EU MDR rollouts rather than super-cycle products abroad yet.
The quarter showed that the base business is still growing strongly while the new-product cycle is starting to contribute. Management believes the new launches should support higher margins, stronger cash generation, and better leverage as they move into fuller commercialization in 2027 and beyond. OPSB, international, and legacy implant share gains all continue to perform, giving the company multiple growth drivers.
Management repeatedly said many of the new products are still early and not yet meaningfully contributing, so the bigger financial payoff may not arrive until 2027 or later. Clinic expansion, set deployment, and product rollouts require cash and can pressure near-term expenses, and management acknowledged some Q4 variability from set sales timing and Brazil. The company also still faces execution risk around FDA timing for eLLi and the pace of broader launches like 3P Small, 3P Mini, and PNP Retrograde.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 69.7%
- Shares Outstanding
- 26.11M
- Float Shares
- 18.20M
of shares held by institutions
121 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Congressional trading
Senate and House stock disclosures for KIDS, newest first.
Source: public STOCK Act disclosures. Filed weeks after the trade — a lagging signal, not a real-time one.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Brown Advisory Inc | 1.61M | ▼ 71.92K |
| Blackrock, Inc. | 1.29M | ▲ 17.60K |
| Aigh Capital Management LLC | 1.17M | ▲ 902.00K |
| Braidwell LP | 1.10M | 0 |
| Vanguard Group Inc | 970.45K | ▲ 9.12K |
| Granahan Investment Management, LLC | 857.00K | ▼ 228.97K |
| Vanguard Capital Management LLC | 751.68K | ▼ 3.94K |
| Wellington Management Group Llp | 743.44K | ▼ 50.87K |
| Soleus Capital Management, L.P. | 710.20K | ▼ 21.95K |
| Morgan Stanley | 602.22K | ▼ 91.16K |
| Dimensional Fund Advisors LP | 497.45K | ▲ 16.61K |
| Wasatch Advisors LP | 469.45K | ▼ 46.23K |
Held by 146 ETFs
Biggest fund positions in KIDS by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Sep 10, 26 | Squadron Capital LLC | sell | 302,369 |
| Sep 10, 26 | Pritzker Jennifer N. | sell | 302,369 |
| Sep 10, 26 | Pelizzon David R | sell | 302,369 |
| Sep 2, 26 | Squadron Capital LLC | sell | 22,500 |
| Sep 2, 26 | Pritzker Jennifer N. | sell | 22,500 |
| Sep 2, 26 | Pelizzon David R | sell | 22,500 |
| Aug 28, 26 | Squadron Capital LLC | sell | 326,700 |
| Sep 1, 26 | Squadron Capital LLC | sell | 10,131 |
| Aug 28, 26 | Pritzker Jennifer N. | sell | 326,700 |
| Sep 1, 26 | Pritzker Jennifer N. | sell | 10,131 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our KIDS coverage
Recent articles, reports, and earnings notes.
No research on KIDS yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate KIDS report →ICE Mortgage Monitor: 2.4 Million Mortgage Holders Are Equity Millionaires as Q3 Home Equity Hits Record High
gurufocus.com · Nov 9
OrthoPediatrics Announces Full Commercial Launch of VerteGlide® Spinal Growth Guidance System
globenewswire.com · Nov 9
OrthoPediatrics to Participate in Upcoming Conferences
globenewswire.com · Nov 2
All You Need to Know About OrthoPediatrics (KIDS) Rating Upgrade to Buy
zacks.com · Oct 30
OrthoPediatrics Corp. (KIDS) Q3 2026 Earnings Call Transcript
seekingalpha.com · Oct 28
OrthoPediatrics: 3 Key Takeaways for Long-Term Investors
fool.com · Oct 27
OrthoPediatrics Q3 Earnings Call Highlights
marketbeat.com · Oct 27
OrthoPediatrics (KIDS) Reports Q3 Loss, Tops Revenue Estimates
zacks.com · Oct 27
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.